Cardinal Health Reports Strong Pharma Segment Growth Amid IRA Pricing Adjustments
Cardinal Health's pharmaceutical segment saw strong demand across specialty, generics, and consumer health in Q3 2026 despite revenue headwinds from the Inflation Reduction Act (IRA) pricing adjustments. The GMPD segment profit declined due to tariffs but showed mid-single-digit growth for five consecutive quarters.
Tickers: $CAH
Topics: goodwill_impairment growth_outlook pharma specialty_pharma supply_chain tariffs